Combination of Laser Photocoagulation and Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity.

The response to combined laser photocoagulation and a single intravitreal injection of 0.75 mg bevacizumab to each eye on separate days in two patients with aggressive, posterior retinopathy of prematurity (ROP) is described. Combined treatment resulted in regression of zone-1 disease in Case 1, which had no retinal detachment. However, no significant regression or unfavorable anatomic response was observed in the second case with retinal detachment. Although the combination of laser photocoagulation and intravitreal bevacizumab injection seems to be well tolerated, inducing prompt regression of agressive zone-1 ROP without retinal detachment, further controlled studies with long-term follow-up are necessary for their use in the treatment of ROP with for potentially dangerous growth factor inhibitors in premature babies.

[1]  A. Negi,et al.  Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  J. Kim,et al.  Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  I. Prieto,et al.  Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. , 2007, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[4]  Lois E. H. Smith,et al.  Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. , 2006, Archives of ophthalmology.

[5]  J. Flynn,et al.  Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. , 2006, American journal of ophthalmology.

[6]  Bradley T. Smith,et al.  Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). , 2006, Molecular vision.

[7]  M. Hartnett,et al.  VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. , 2004, Molecular vision.

[8]  A. Fielder,et al.  Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. , 2003, Archives of ophthalmology.

[9]  Lois E. H. Smith.  Pathogenesis of retinopathy of prematurity. , 2003, Seminars in neonatology : SN.

[10]  D. S. Mcleod,et al.  Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. , 2002, Investigative ophthalmology & visual science.

[11]  Helen L. Naug,et al.  Vitreal macrophages express vascular endothelial growth factor in oxygen‐induced retinopathy , 2000, Clinical & experimental ophthalmology.

[12]  A. Albert,et al.  Effect of the environment on fetal skin wound healing. , 1997, Journal of pediatric surgery.

[13]  H. Dvorak,et al.  Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. , 1996, Archives of ophthalmology.

[14]  S. Mandriota,et al.  Transforming Growth Factor 1 Down-regulates Vascular Endothelial Growth Factor Receptor 2/flk-1 Expression in Vascular Endothelial Cells (*) , 1996, The Journal of Biological Chemistry.

[15]  I. K. Cohen,et al.  Transforming growth factor beta (TGF-β) induces fibrosis in a fetal wound model , 1988 .